Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.

ABSTRACT: Hepatic fibrosis and advanced fibrosis in particular is the strongest predictor of liver-related outcomes and mortality among nonalcoholic steatohepatitis (NASH) patients. Understanding prevalence and predictors of NASH with advanced fibrosis is critical for healthcare resource planning. Using a large U.S. clinical laboratory database from 10/1/2017-9/30/2018, adults negative for hepatitis B and hepatitis C and after excluding for alcoholic liver disease and pregnancy were evaluated for prevalence of F3 and F4 fibrosis using a systematic algorithm of five fibrosis-4 (FIB-4) criteria: Criteria 1 (≥F3: >2.67), Criteria 2 (2.674.12), Criteria 3 (2.673.15), Criteria 4 (3.253.5), Criteria 5 (3.254.12). Metabolic co-morbidities evaluated incl

SUBMITTER: Wong RJ 

PROVIDER: S-EPMC6675045 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature